Lyra Therapeutics, Inc. – NASDAQ:LYRA
Lyra Therapeutics stock price today
$7.09
+6.89
+3621.78%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Lyra Therapeutics stock price monthly change
-34.36%
month
Lyra Therapeutics stock price quarterly change
-34.36%
quarter
Lyra Therapeutics stock price yearly change
-96.25%
year
Lyra Therapeutics key metrics
Market Cap | 11.27M |
Enterprise value | 45.25M |
P/E | -1.3 |
EV/Sales | 6.34 |
EV/EBITDA | -0.59 |
Price/Sales | 10.59 |
Price/Book | 0.93 |
PEG ratio | -0.02 |
EPS | -1.24 |
Revenue | 1.68M |
EBITDA | -69.92M |
Income | -68.87M |
Revenue Q/Q | 29.75% |
Revenue Y/Y | 41.53% |
Profit margin | -1075.72% |
Oper. margin | -1090.79% |
Gross margin | 5.03% |
EBIT margin | -1090.79% |
EBITDA margin | -4162.26% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLyra Therapeutics stock price history
Lyra Therapeutics stock forecast
Lyra Therapeutics financial statements
| Jun 2023 | 458K | -15.61M | -3410.04% |
|---|---|---|---|
| Sep 2023 | 544K | -15.65M | -2877.02% |
| Dec 2023 | 146K | -15.15M | -10380.82% |
| Mar 2024 | 532K | -22.45M | -4220.3% |
| Sep 2025 | 203.5K | -13.71M | -6740.63% |
|---|---|---|---|
| Oct 2025 | 118K | -14.40M | -12205.56% |
| Dec 2025 | 203.5K | -13.20M | -6487.4% |
| Dec 2025 | 118K | -13.44M | -11391.85% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 125675000 | 27.09M | 21.56% |
|---|---|---|---|
| Sep 2023 | 120575000 | 36.33M | 30.14% |
| Dec 2023 | 142600000 | 53.18M | 37.29% |
| Mar 2024 | 141527000 | 64.02M | 45.24% |
| Jun 2023 | -14.28M | -561K | 47.18M |
|---|---|---|---|
| Sep 2023 | -14.11M | -14.97M | -418K |
| Dec 2023 | -19.05M | -2.35M | 18.92M |
| Mar 2024 | -22.45M | 7.85M | 8.64M |
Lyra Therapeutics alternative data
| Aug 2023 | 64 |
|---|---|
| Sep 2023 | 73 |
| Oct 2023 | 73 |
| Nov 2023 | 73 |
| Dec 2023 | 78 |
| Jan 2024 | 78 |
| Feb 2024 | 78 |
| Mar 2024 | 88 |
| Apr 2024 | 88 |
| May 2024 | 88 |
| Jun 2024 | 109 |
| Jul 2024 | 109 |
Lyra Therapeutics other data
0.69%
-51.11%
of LYRA is owned by hedge funds
11
-25
207.83K
-18.86M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 10832496 | 0 |
| Nov 2023 | 25000 | 0 |
| Patent |
|---|
Application Filling date: 4 Mar 2021 Issue date: 24 Jun 2021 |
Application Filling date: 7 Dec 2020 Issue date: 10 Jun 2021 |
Grant Filling date: 13 Dec 2016 Issue date: 13 Apr 2021 |
Application Filling date: 28 Sep 2020 Issue date: 11 Mar 2021 |
Grant Filling date: 5 Nov 2018 Issue date: 15 Dec 2020 |
Grant Filling date: 5 Nov 2018 Issue date: 8 Dec 2020 |
Application Filling date: 20 Apr 2018 Issue date: 26 Nov 2020 |
Grant Filling date: 26 Nov 2018 Issue date: 20 Oct 2020 |
Application Filling date: 3 Apr 2020 Issue date: 8 Oct 2020 |
Application Filling date: 7 Apr 2020 Issue date: 23 Jul 2020 |
| Quarter | Transcript |
|---|---|
| Q3 2021 9 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 9 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Q1 2021 11 May 2021 | Q1 2021 Earnings Call Transcript |
| Q4 2020 9 Mar 2021 | Q4 2020 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Maria Palasis Ph.D. (1965) Chair of the Board, Chief Executive Officer & Pres | $754,070 |
Mr. R. Donald Elsey MBA (1954) Advisor | $536,340 |
| Dr. Robert Richard Ph.D. (1957) Senior Vice President of R&D | $366,740 |
3 'Buy-Rated' Biotech Stocks Under $10
Lyra Therapeutics: Hold For Phase 3 Topline
Lyra Therapeutics' Nasal Matrix In Focus: Sniffing Out Opportunity
Lyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus Treatment
Lyra Therapeutics: Negative EV With A Very Compelling Treatment For Chronic Rhinosinusitis In Phase 3
Lyra Therapeutics: Progress In The Clinic
Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor
-
What's the price of Lyra Therapeutics stock today?
One share of Lyra Therapeutics stock can currently be purchased for approximately $7.09.
-
When is Lyra Therapeutics's next earnings date?
Unfortunately, Lyra Therapeutics's (LYRA) next earnings date is currently unknown.
-
Does Lyra Therapeutics pay dividends?
No, Lyra Therapeutics does not pay dividends.
-
How much money does Lyra Therapeutics make?
Lyra Therapeutics has a market capitalization of 11.27M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 14.31% to 1.56M US dollars.
-
What is Lyra Therapeutics's stock symbol?
Lyra Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "LYRA".
-
What is Lyra Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Lyra Therapeutics?
Shares of Lyra Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Lyra Therapeutics's key executives?
Lyra Therapeutics's management team includes the following people:
- Dr. Maria Palasis Ph.D. Chair of the Board, Chief Executive Officer & Pres(age: 60, pay: $754,070)
- Mr. R. Donald Elsey MBA Advisor(age: 71, pay: $536,340)
- Dr. Robert Richard Ph.D. Senior Vice President of R&D(age: 68, pay: $366,740)
-
How many employees does Lyra Therapeutics have?
As Jul 2024, Lyra Therapeutics employs 109 workers, which is 24% more then previous quarter.
-
When Lyra Therapeutics went public?
Lyra Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 1 May 2020.
-
What is Lyra Therapeutics's official website?
The official website for Lyra Therapeutics is lyratherapeutics.com.
-
Where are Lyra Therapeutics's headquarters?
Lyra Therapeutics is headquartered at 480 Arsenal Way, Watertown, MA.
-
How can i contact Lyra Therapeutics?
Lyra Therapeutics's mailing address is 480 Arsenal Way, Watertown, MA and company can be reached via phone at +61 73934600.
Lyra Therapeutics company profile:
Lyra Therapeutics, Inc.
lyratherapeutics.comExchange:
NASDAQ
Full time employees:
88
Industry:
Biotechnology
Sector:
Healthcare
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
480 Arsenal Way
Watertown, MA 02472
Watertown, MA 02472
CIK: 0001327273
ISIN: US55234L1052
CUSIP: 55234L105
